Breaking News
Investing Pro 0
Cyber Monday Extended SALE: Up to 60% OFF InvestingPro+ CLAIM OFFER
Close

BioCryst Pharmaceuticals Inc (BCRX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow BioCryst's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
12.79 -0.17    -1.31%
02/12 - Closed. Currency in USD ( Disclaimer )
After Hours
12.70
-0.09
-0.70%
17:22:37 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,835,666
  • Bid/Ask: 12.60 / 12.91
  • Day's Range: 12.69 - 12.93
BioCryst 12.79 -0.17 -1.31%

BCRX Earnings

 
The latest earnings per stock, revenues and financial reports for BioCryst Pharmaceuticals Inc (BCRX).
InvestingPro Earnings Insights
Latest Release

Nov 02, 2022

EPS / Forecast

-0.23 / -0.29

Revenue / Forecast

75.83M / 74.62M

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Feb 28, 2023 12/2022 -- /  -0.1827 -- /  77M
Nov 02, 2022 09/2022 -0.23 /  -0.29 75.83M /  74.62M
Aug 04, 2022 06/2022 -0.32 /  -0.3436 65.53M /  63.33M
May 05, 2022 03/2022 -0.4 /  -0.3625 49.92M /  51.36M
Feb 23, 2022 12/2021 -0.1 /  -0.295 47.16M /  51.06M
Nov 03, 2021 09/2021 -0.33 /  -0.2927 40.99M /  40.2M
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View upcoming earnings forecasts and in-depth analysis of company forecasts.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BCRX Comments

Write your thoughts about BioCryst Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jean Mercredi
Jean Mercredi Oct 04, 2022 10:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Back on track
Giuseppe Giannachi
Giuseppe Giannachi Apr 08, 2022 1:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This hammering looks a little too severe.
Kainee Foo
Kainee Foo Apr 08, 2022 11:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what's wrong?
Giuseppe Giannachi
Giuseppe Giannachi Apr 08, 2022 11:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Clinical trial product halt.
Giuseppe Giannachi
Giuseppe Giannachi Apr 08, 2022 9:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Man...
Edwin Henriquez
Edwin Henriquez Feb 23, 2022 9:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what a joke with earnings worse in years and with FDA approval seriously
Edwin Henriquez
Edwin Henriquez Jan 10, 2022 2:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The Food and Drug Administration (FDA) approved BioCryst's first drug, Orladeyo, a little over a year ago. The first few quarters post-launch for the drug, which prevents attacks of hereditary angioedema, were less than inspiring. But preliminary fourth-quarter figures released today suggest the drug really can achieve more than $1 billion in annual sales.
Jean Mercredi
Jean Mercredi Jan 10, 2022 11:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why up so much?
Edwin Henriquez
Edwin Henriquez Jan 10, 2022 11:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
preliminary earnings is looking super good 👌
Carolina Echegoyen
Carolina Echegoyen Dec 22, 2021 6:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
premaket down 6,90 %, any news?'
Jean Mercredi
Jean Mercredi Nov 03, 2021 12:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Earnings were bad?
Francesco Mnemotron
Francesco Mnemotron Nov 03, 2021 12:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
not really
Adam Dege
Adam Dege Nov 03, 2021 9:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email